Fundamental Analysis of Baudax Bio Inc - Growth / Value Index
BXRX - Valuation Highlights
Valuation Analysis
Price to Earning Ratio is 0.0035 and EV to EBITDA is 0.053 suggesting company is undervalued.
Book value is negative
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 0.0035 | % | ||
| Price to Book | -0.0030 | 0 | 0 % | -0.067 |
| Price to Sales | 0.098 | 0 | 0 % | |
| Enterprise Value to EBITDA Multiple | 0.053 | 0 | 0 % |
BXRX - Profitability Highlights
Profitability Analysis
Earning Yield of 28813.36 %
During the past twelve months, the company has given a strong Return On Asset of 60.24%
During the past twelve months, the company has given a strong Net Margin of 2836.00%
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Piotroski F Score - Very Poor Value of 2.0
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 0 | 0 % | 0 | |
| Return On Asset | 60.24 | 0 | 0 % | -0.209 |
| Net Profit Margin | 2836.00 | -563.75 | 87.83 % | 0 |
| Operating Profit Margin | 3162.77 | -2759.89 | 38.35 % | 0 |
| EBITDA Margin | 2552.31 | -385.74 | 91.65 % | 0 |
Highlights
| Market Cap | 435931 |
| Enterprise Value | 435931 |
| Price/Book TTM | -0.0030 |
| Outstanding Share | 43593.10 K |
| Float/ Outstanding Share | 99.99% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 2.00 |
| Altman Z Score | |
| Sloan Ratio | |
| Peter Lynch Fair Value | 72.03 |
BXRX - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Tsr Growth Index - Poor Score of 25.38
Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 325000 | 0 % | 100.00 % |
| Gross Profit | -5019.00 K | 100.00 % | 41.89 % |
| EBITDA | 8295.00 K | 91.65 % | 41.89 % |
| Net Profit | 9217.00 K | 87.83 % | 41.89 % |
| EPS | 2.88 | 100.00 % | NA |
BXRX - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 95.00
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0 | 0 % | -0.446 |
| Cash Ratio | 0 | 0 % | |
| Quick Ratio | 0 | 0 % | 0.070 |
| Shareholders Equity | 0 | 0 % | |
| Debt to EBITDA | 0 | 0 % |
Historical Valuation Ratios of Baudax Bio Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Baudax Bio Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Baudax Bio Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Baudax Bio Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)